Allosteric Inhibitor Screening + Synthetic Lethality Discovery Platform
Provider 
Founded 2020
Sells To Enterprise
Pricing Model Recurring, Software
Ownership Private

Allosteric screening and synthetic lethality platforms with 200k library.
Mass spectrometry-based allosteric inhibitor screening platform plus phenotypic/chemical/CRISPR synthetic lethality discovery platform. Includes AI-enabled chemoinformatics, bioinformatics, and proprietary ~200,000 compound library.
Platforms validated by clinical candidates. Supports first-in-class oncology and autoimmune programs and BD partnerships.
Jacobio Pharma

Induced Allosteric Drug Discovery Platform
jacobiopharma.com
Gain Therapeutics

Magellan Platform
gaintherapeutics.com
Tango Therapeutics

Synthetic Lethality Discovery Platform
tangotx.com
Adds products that compete with one of Allosteric Inhibitor Screening + Synthetic Lethality Discovery Platform’s direct competitors but not with Allosteric Inhibitor Screening + Synthetic Lethality Discovery Platform itself. They are shaded, and Linked Through names the direct competitor each one competes with.
| Attribute | Allosteric Inhibitor Screening + Synthetic Lethality Discovery Platform | Induced Allosteric Drug Discovery Platform | Magellan Platform | Synthetic Lethality Discovery Platform | |
|---|---|---|---|---|---|
| Provider | |||||
| Founded | 2020 | 2015 | 2017 | 2017 | |
| Sells To | Enterprise | Enterprise, Government | Enterprise | Enterprise | |
| Pricing Model | Recurring, Software | Recurring | Recurring, Software | Recurring, Software | |
| Ownership | Private | Public | Venture-backed | Private equity-backed, Venture-backed |
Provider 
Founded 2020
Sells To Enterprise
Pricing Model Recurring, Software
Ownership Private
Provider 
Founded 2015
Sells To Enterprise, Government
Pricing Model Recurring
Ownership Public
Provider 
Founded 2017
Sells To Enterprise
Pricing Model Recurring, Software
Ownership Venture-backed
Provider 
Founded 2017
Sells To Enterprise
Pricing Model Recurring, Software
Ownership Private equity-backed, Venture-backed


Smart Allostery Platform is HotSpot Therapeutics' allosteric drug discovery platform for targeting disease-driving proteins.


AI-guided cyclic-oligonucleotide platform for designing ASO, siRNA, and sgRNA drug candidates.


Biology-First AI platform predicts disease-matched compounds using multi-omics human data and functional validation.


AlphaSeq is a multiplexed platform from A-Alpha Bio for quantitative measurement of protein interactions.


Dynamo Platform is Relay Therapeutics' Motion-Based Drug Design platform for finding novel allosteric binding sites on validated targets.
Smart Allostery Platform is HotSpot Therapeutics' allosteric drug discovery platform for targeting disease-driving proteins.

AI-guided cyclic-oligonucleotide platform for designing ASO, siRNA, and sgRNA drug candidates.

Biology-First AI platform predicts disease-matched compounds using multi-omics human data and functional validation.

AlphaSeq is a multiplexed platform from A-Alpha Bio for quantitative measurement of protein interactions.

Dynamo Platform is Relay Therapeutics' Motion-Based Drug Design platform for finding novel allosteric binding sites on validated targets.
